Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Comparative Effectiveness of Different Lung Cancer Treatments

Principal Investigator
Name
Chi-Fu Yang
Degrees
M.D.
Institution
Stanford
Position Title
Fellow
Email
About this CDAS Project
Study
NLST (Learn more about this study)
Project ID
NLST-675
Initial CDAS Request Approval
Jun 9, 2020
Title
Comparative Effectiveness of Different Lung Cancer Treatments
Summary
Currently, numerous national retrospective studies of clinical and administrative databases have evaluated the effectiveness of different treatments for stage I-IV lung cancer. However, those databases are often missing important information, such as data on COPD or smoking history. The objective of this research project is to evaluate the effectiveness of different treatments for stage I-IV lung cancer using the NLST, which contains important variables such as COPD or smoking history.
Aims

Aim #1: To compare the outcomes associated with different surgical and non-operative treatments for stage I-IV lung cancer

Aim #2: To evaluate the impact of delays to care on short-term and long-term outcomes on patients with stage I-IV lung cancer.

Aim #3: To evaluate the outcomes associated with delayed treatment vs timely treatment and evaluate optimal time intervals for treatment for stage I-IV lung cancer.

Aim #4: To identify patterns and trends in lung cancer care and outcomes that are related to socioeconomic and racial disparities.

Aim #5: To evaluate how various patient demographic, clinical, and pathologic factors could be associated with or impact short-term and long-term outcomes for patients with stage I-IV lung cancer.

Aim #6: To develop risk prediction models that address Aims #1-#6

Collaborators

Nicholas Mayne, Duke
Vignesh Raman, Duke
John Deng, UCLA
Yoyo Wang, Michigan
Alexandra Potter, UC Berkeley
Alice Darling, Duke
Holly Elser, Stanford
Douglas Liou, Stanford
Belle Lin, University of Arizona

Related Publications